ABELCET® (amphotericin B lipid complex injection) is indicated for the treatment of invasive fungal infections in patients who cannot tolerate or have failed conventional amphotericin B therapy.
ABELCET is a broad-spectrum antifungal used primarily in the hospital setting to treat fungal infections in patients with compromised immune systems, such as those undergoing treatment for cancer and recipients of organ or bone marrow transplants.
ABELCET offers broad-spectrum activity against many of today’s most threatening yeast and mould pathogens, including Aspergillus, Zygomycetes, Fusarium, Cryptococcus, and many hard-to-treat Candida species. Amphotericin B, the active ingredient in ABELCET, is believed to act by penetrating the cell wall of a fungus, thereby killing it. Treatment with ABELCET and other amphotericin B agents rarely leads to acquired fungal resistance.
The safety and tolerability profile of ABELCET has been well established over 10 years of clinical use. ABELCET is associated with significantly lower renal toxicity when compared to conventional amphotericin B.
ABELCET is contraindicated in patients who have shown hypersensitivity to amphotericin B or any component in the formulation. Anaphylaxis has been reported with amphotericin B desoxycholate and other amphotericin B-containing drugs (<0.1% incidence rate with ABELCET). Despite generally less nephrotoxicity of ABELCET observed at a dose of 5 mg/kg/day compared with conventional amphotericin B therapy at a dose range of 0.6-1 mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET. Renal toxicity of doses greater than 5 mg/kg/day of ABELCET has not been formally studied. The adverse events most commonly reported with ABELCET are transient chills and/or fever during infusion of the drug.
Click here for full prescribing information for ABELCET.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Click here for contact information.